Based on the above research results, we verified by network pharmacology technology the potential targets of luteolin in the treatment of hepatocellular carcinoma angiogenesis include AKT1, SRC, EGFR, ESR1, MMP9, and PTGSR (Figure 5B). Here, ESR1 is linked to hepatocellular carcinoma.